Eli Lilly and Pfizer drugs now on China’s private insurance list for cancer, Alzheimer’s, and rare diseases.

Eli Lilly and Pfizer have been added to China’s first private insurance drug list, announced in Guangzhou, expanding access to innovative treatments for conditions like cancer, Alzheimer’s, and rare genetic disorders. The move, part of a broader effort to integrate private insurance with advanced therapies, signals growing collaboration between global pharmaceutical firms and China’s evolving healthcare system. While specific drugs and coverage details were not disclosed, the initiative aims to reduce patient costs and support healthcare modernization.